| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Cardiology, Seattle Veterans Affairs Medical Center and Departments of Radiology and Radiation Oncology, University of Washington, Seattle, Washington
Correspondence: For correspondence or reprints contact: Gary V. Martin, MD, Division of Cardiology (111c), Veterans Affairs Medical Center, 1660 South Columbian Way, Seattle, WA 98108.
ABSTRACT
Misonidazole and related compounds are metabolically trapped in viable cells as a function of reduced cellular pO2. [18F]fluoro-misonidazole has been used to detect hypoxia in the heart and in tumors noninvasively with positron emission tomography. The purpose of this study was to characterize the uptake of the iodinated misonidazole congener iodovinylmisonidazole (IVM) in ischemic myocardium. In six open chest dogs (Group 1), the left anterior descending (LAD) coronary artery was partially occluded and in four dogs (Group 2), demand ischemia was produced by the combination of a trial pacing and catecholamine infusion in the presence of a LAD stenosis. [131I]IVM (5–15 µCi/kg, iv.) was given following the onset of ischemia. Tracer deposition was measured by postmortem tissue sampling 4 hr postinjection and compared to microsphere myocardial blood flow (MBF) measurements made at baseline and at 2 hr postinjection. In Group 1, regional IVM deposition in heart samples within the ischemic area was inversely related to MBF with maximum tissue:blood ratios of 3.2. For a given level of reduced blood flow, IVM uptake was higher in the subendocardium indicating a greater vulnerability of the subendocardium to reductions in oxygen delivery. In Group 2, enhanced IVM deposition was detected as a result of demand ischemia, even in some regions where absolute flow was normal or increased from baseline, indicating that flow per se is not the principal determinant of tracer uptake. We conclude that IVM is a promising marker for myocardial hypoxia with potential clinical application using gamma camera imaging.
This article has been cited by other articles:
|
|
 |
|
  S. H. Britz-Cunningham and S. J. Adelstein Molecular Targeting with Radionuclides: State of the Science J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Okada, G. Johnson III, K. N. Nguyen, Z. Liu, B. Edwards, C. M. Archer, T. L. North, A. C. King, and J. D. Kelly 99mTc-HL91 : "Hot Spot" Detection of Ischemic Myocardium In Vivo by Gamma Camera Imaging Circulation, June 30, 1998; 97(25): 2557 - 2566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Okada, G. Johnson III, K. N. Nguyen, B. Edwards, C. M. Archer, and J. D. Kelly 99mTc-HL91 : Effects of Low Flow and Hypoxia on a New Ischemia-Avid Myocardial Imaging Agent Circulation, April 1, 1997; 95(7): 1892 - 1899. [Abstract] [Full Text]
|
|
|
|
|
|
M. Berman, A. J. Fischman, J. Southern, E. Carter, F. Mirecki, H. W. Strauss, A. Nunn, and H. Gewirtz Myocardial Adaptation During and After Sustained, Demand-Induced Ischemia: Observations in Closed-Chest, Domestic Swine Circulation, August 15, 1996; 94(4): 755 - 762. [Abstract] [Full Text]
|
|
|
|
|
|
C. K. Stone, T. Mulnix, R. J. Nickles, B. Renstrom, S. H. Nellis, A. J. Liedtke, A. D. Nunn, B. L. Kuczynski, and W. L. Rumsey Myocardial Kinetics of a Putative Hypoxic Tissue Marker, 99mTc-Labeled Nitroimidazole (BMS-181321), After Regional Ischemia and Reperfusion Circulation, September 1, 1995; 92(5): 1246 - 1253. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
